Weiss, Glen J <br/><br/>
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.  [electronic resource] 

 -  Investigational new drugs  Dec 2012 
 - 2334-43 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-011-9774-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Cyclin-Dependent Kinases--antagonists & inhibitors<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyrazoles--administration & dosage<br/>Quinazolines--administration & dosage<br/>Receptor, trkA--antagonists & inhibitors<br/>Treatment Outcome<br/>Young Adult